1997
DOI: 10.1007/bf02551427
|View full text |Cite
|
Sign up to set email alerts
|

The effect of calcitriol on renal anaemia in patients undergoing long-term dialysis

Abstract: In long-term haemodialysis patients suffering from secondary hyperparathyroidism Se iPTH could be suppressed by an intravenous calcitriol therapy. As the Se iPTH level became reduced, lower doses of Rh-EPO were already sufficient for the maintenance of the target haematocrit, while in two patients not requiring Rh-EPO treatment an improvement of their moderate anaemia could be observed. These data corroborate the view that calcitriol is an effective drug in secondary hyperparathyroidism. The results suggest th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
5
0

Year Published

2002
2002
2016
2016

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(5 citation statements)
references
References 17 publications
0
5
0
Order By: Relevance
“…However, results must be considered preliminary since no control group was included in the two studies. In another study in hemodialysis patients, intravenous administration of 1,25(OH) 2 D decreased the weekly EPO dose requirement by 50% [ 35 ]. Similarly, high-dose monthly oral vitamin D 2 administration (50,000 IU) was associated with non-significant [ 36 ] and significant [ 37 ] reductions in doses of erythropoiesis-stimulating agents (ESA), while mean Hb levels remained unchanged.…”
Section: Discussionmentioning
confidence: 99%
“…However, results must be considered preliminary since no control group was included in the two studies. In another study in hemodialysis patients, intravenous administration of 1,25(OH) 2 D decreased the weekly EPO dose requirement by 50% [ 35 ]. Similarly, high-dose monthly oral vitamin D 2 administration (50,000 IU) was associated with non-significant [ 36 ] and significant [ 37 ] reductions in doses of erythropoiesis-stimulating agents (ESA), while mean Hb levels remained unchanged.…”
Section: Discussionmentioning
confidence: 99%
“…The results of this study are consistent with previous studies of dialysis patients in which vitamin D supplementation with ergocalciferol and calcitriol appeared to increase sensitivity to erythropoietin as evidenced by a lower requirement for erythropoiesis-stimulating agents to achieve similar control of anemia. 13,[15][16][17] Additionally, in a recent cross-sectional analysis of the Third National Health and Nutrition Examination Study (NHANES III), lower 25D levels were independently associated with lower hemoglobin concentrations within the CKD population. 6 We confirm these results in this study, but also extend them in two important ways.…”
Section: Discussionmentioning
confidence: 99%
“…4,14 Indeed, previous studies have suggested improved control of anemia in dialysis patients treated with active forms of vitamin D such as calcitriol or nutritional vitamin D precursors such as ergocalciferol. 13,[15][16][17] Given these associations, the high prevalence of anemia and 25-hydroxyvitamin D (25D) and 1,25D deficiency in CKD, and the abundant availability of therapies for correcting these deficiencies, we undertook a cross-sectional analysis of a cohort of pre-dialysis CKD patients to test the hypothesis that deficiencies in the vitamin D axis, both 25D and 1,25D, are independently associated with lower hemoglobin levels and higher prevalence of anemia in early CKD.…”
mentioning
confidence: 99%
“…In chronic kidney disease (CKD) patients, some nonrandomized intervention studies could already show that intravenous administration of activated vitamin D (1,25-dihydroxyvitamin D3 = 1,25(OH) 2 D 3 ) is associated with an increase in Hb levels within 12 months of treatment and a reduced need for erythropoietin (EPO) [ 16 , 17 ]. Moreover, intravenous 1,25(OH) 2 D 3 administration was associated with a decreased weekly EPO dose of 50% [ 18 ]. Regarding Hb levels, similar results have been obtained in hemodialysis patients with oral alfacalcidol (1 α -vitamin D 3 ) after 8 weeks [ 19 ] and also after 12 and 18 months of treatment [ 20 ].…”
Section: Introductionmentioning
confidence: 99%